Novartis AG (NYSE:NVS) Shares Sold by Radnor Capital Management LLC

Radnor Capital Management LLC reduced its holdings in Novartis AG (NYSE:NVS) by 16.5% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 5,450 shares of the company’s stock after selling 1,075 shares during the quarter. Radnor Capital Management LLC’s holdings in Novartis were worth $530,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Financial & Tax Architects LLC boosted its stake in shares of Novartis by 32.8% during the 2nd quarter. Financial & Tax Architects LLC now owns 4,703 shares of the company’s stock worth $501,000 after acquiring an additional 1,161 shares in the last quarter. Wealth Alliance boosted its position in shares of Novartis by 5.5% in the 2nd quarter. Wealth Alliance now owns 3,683 shares of the company’s stock valued at $392,000 after purchasing an additional 191 shares during the period. Mercer Global Advisors Inc. ADV increased its stake in Novartis by 3.6% in the 2nd quarter. Mercer Global Advisors Inc. ADV now owns 153,055 shares of the company’s stock worth $16,294,000 after purchasing an additional 5,285 shares in the last quarter. Argent Trust Co raised its holdings in Novartis by 4.6% during the 2nd quarter. Argent Trust Co now owns 35,575 shares of the company’s stock worth $3,787,000 after buying an additional 1,574 shares during the period. Finally, Vanguard Personalized Indexing Management LLC lifted its stake in Novartis by 19.4% during the second quarter. Vanguard Personalized Indexing Management LLC now owns 69,774 shares of the company’s stock valued at $7,324,000 after buying an additional 11,355 shares in the last quarter. 13.12% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

NVS has been the topic of several analyst reports. HSBC downgraded shares of Novartis from a “hold” rating to a “reduce” rating in a research report on Wednesday, December 4th. BMO Capital Markets boosted their target price on shares of Novartis from $118.00 to $120.00 and gave the company a “market perform” rating in a research note on Wednesday, October 30th. Finally, Erste Group Bank reaffirmed a “hold” rating on shares of Novartis in a research report on Tuesday, November 19th. Two analysts have rated the stock with a sell rating and seven have assigned a hold rating to the company’s stock. According to MarketBeat, Novartis presently has an average rating of “Hold” and a consensus target price of $121.50.

Novartis Stock Down 0.3 %

Novartis stock opened at $99.05 on Thursday. The firm’s 50 day moving average price is $101.13 and its two-hundred day moving average price is $109.19. The firm has a market cap of $202.46 billion, a PE ratio of 11.50, a P/E/G ratio of 1.36 and a beta of 0.57. Novartis AG has a twelve month low of $92.35 and a twelve month high of $120.92. The company has a debt-to-equity ratio of 0.55, a quick ratio of 0.90 and a current ratio of 1.11.

Novartis (NYSE:NVS) last announced its quarterly earnings data on Tuesday, October 29th. The company reported $2.06 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.94 by $0.12. Novartis had a return on equity of 34.80% and a net margin of 35.96%. The business had revenue of $12.82 billion during the quarter, compared to analyst estimates of $12.62 billion. During the same period last year, the company earned $1.74 earnings per share. On average, research analysts predict that Novartis AG will post 7.63 EPS for the current fiscal year.

Novartis Company Profile

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.